Axsome Therapeutics (AXSM) EBIT (2015 - 2026)

Axsome Therapeutics has reported EBIT for 12 years, with the latest figure at -$63.4 million in Q1 2026.

• Quarterly EBIT fell 11.19% year-over-year to -$63.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$173.1 million (up 35.94% YoY) and the FY2025 annual result came in at -$166.8 million, up 40.56% from the prior year.
• EBIT retreated to -$63.4 million in Q1 2026 per AXSM's latest filing, from -$27.0 million in the prior quarter.
• Over five years, EBIT peaked at -$6.4 million in Q1 2023 and troughed at -$98.3 million in Q4 2023.
• A 5-year average of -$54.3 million and a median of -$59.9 million in 2022 frame the typical range for EBIT.
• The sharpest annual moves came in 2023 and 2024: EBIT surged 83.35% in 2023, then tumbled 955.46% in 2024.
• Over 5 years, EBIT stood at -$59.9 million in 2022, then plunged by 64.01% to -$98.3 million in 2023, then grew by 26.11% to -$72.6 million in 2024, then soared by 62.88% to -$27.0 million in 2025, then slumped by 135.03% to -$63.4 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$63.4 million, -$27.0 million, and -$46.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.